Baker Bros. Advisors’s Mersana Therapeutics MRSN Stock Holding History

Baker Bros. Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43,445	Closed	-$1.55M	–	95
2024 Q4	$1.55M	Hold	43,445	–	–	0.02%	86
2024 Q3	$2.05M	Hold	43,445	–	–	0.02%	80
2024 Q2	$2.18M	Hold	43,445	–	–	0.03%	79
2024 Q1	$4.87M	Hold	43,445	–	–	0.06%	62
2023 Q4	$2.52M	Hold	43,445	–	–	0.03%	70
2023 Q3	$1.38M	Hold	43,445	–	–	0.01%	93
2023 Q2	$3.57M	Sell	43,445 -32,000	-42%	-$4.68M	0.02%	83
2023 Q1	$7.75M	Buy	+75,445	New	+$10.6M	0.04%	59

Other funds holding MRSN

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return

AQR Capital Management

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return